02.08.2022 • News3Mhealthcare

3M to Separate Healthcare Business

US conglomerate 3M is to spin off its healthcare business in a move that chairman and CEO Mike Roman said will result in “two well-capitalized, world-class public companies, well positioned to pursue their respective priorities.”

The separation is expected to be completed by the end of 2023, subject to customary conditions, including final approval from 3M’s board of directors.

According to 3M, the separated healthcare business will be “a leading global diversified healthcare technology company focused on wound care, healthcare IT, oral care and biopharma filtration,” while New 3M will “remain a leading global material science innovator serving customers across a range of industrial and consumer end markets.”

Healthcare had sales of about $8.61 billion last year, and 3M said its strong track record of profitability and robust cash flow generation makes it well positioned to pursue its strategic objectives and focus on growth. New 3M expects to retain a 19.9% stake in the standalone healthcare company, which will be monetized over time.

The Minnesota-based group will also complete the previously announced separation of its food safety business, which is being combined with Neogen. The closing date for this split-off transaction will be Sept. 1, 2022, subject to approval by Neogen shareholders, regulatory approvals and other customary conditions.

Author: Elaine Burridge, Freelance Journalist

©3M
©3M

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.